Tag Archives: etf

Want To Trade The Interest Rate Swap/Treasury Bond Spread? Think Twice.

The spread between five-year OTC interest rate swap yields and five-year Treasury yields has recently turned negative. In theory, this spread measures the cost depositors charge for bearing the extra credit risk of bank deposits. Should you buy this spread, expecting a return to positive spreads? Trades based on the yield economics are risky in the very inefficient IRS market. The press has awakened to an unexpected development on the long end of the interest rate swap (“IRS”) yield curve. IRS rates for 5-year maturities and longer are trading below Treasury rates for the same maturities. This spread is, in theory , a measure of the difference between the credit risk of Treasury debt and unsecured wholesale unsecured bank debt of the same maturity. But in reality this spread is obviously vulnerable to divergence from the theory. The chart shows the 5-year swap rate against the 5-year constant maturity Treasury curve over the past six months. A few things stand out. The IRS yield exceeded the Treasury yield during most of the period. The problem, if we should call it that, begins with the early-October run-up in Treasury rates, as displayed in the graph below, produced by FRED, the St. Louis Fed’s database. Several issues that distinguish IRS markets from Treasury markets might have come into play at that point. What are the trading implications of this development? With the listing of 5-year IRS futures by the CME Group (NASDAQ: CME ), it is possible for non-banks to trade the expected spread between 5-year IRS futures (CBOT : F1U) and 5-year Treasury note futures (CBOT : ZF). (click to enlarge) But the negative cash market spread is telling us that an analysis of the credit risk of prime banks is secondary in trading this spread successfully at present. There is no assurance that buying this negative spread will return a quick profit. Economic forces will be secondary determinants of this spread until the OTC IRS itself trades in a secondary market. At the moment, determination of swap rates is the dominion of roughly 20 large banks that face a multitude of other problems. On the other hand, if you meet these conditions: You are a non-bank corporate or financial institutions borrower, but not an IRS dealer. You can finance your operations at interest costs tied to 6-month LIBOR for the foreseeable future. You have a productive use for long-term debt. Run – do not walk – to your nearest swap dealer and pay fixed on an appropriately sized IRS at a negative spread to Treasuries. OTC swap dealers do provide long-term interest cost protection. It will take five or more years for the swap to unwind and provide the cheap long-term cost of money that you seek, but if that is consistent with your business plan, very little can go wrong. [But if there is any chance that you will change your mind (as several municipalities have done), do not enter this transaction. There is no more iron-clad commitment than an IRS. It is not a bond. You can’t buy it back.] The IRS/Treasury spread is a close relative of the TED Spread [difference between the Treasury bill rate and the Eurodollar (LIBOR) rate of the same maturity.] The TED spread is thought to represent the cost to prime London banks of the added credit risk their short term unsecured debt represented relative to that of the U.S. Treasury. In spite of the problematic history of LIBOR pricing, the TED spread has been and will remain, positive. LIBOR is indeed problematic. Within months of the listing of Eurodollar futures (CME : ED), LIBOR became something other than a market yield. London offered the services of the British Bankers Association in polling specified bank employees in London branches to form a poll on LIBOR. This was not good news for believers in market forces. Most readers are aware of the sorry history of this “LIBOR fixing,” with billions in legal settlements of lawsuits resulting from manipulation of this poll on a market price. If you are not familiar with the LIBOR scandal, read here . LIBOR, the interest rate index fundamental to the determination of swap values, is an estimate of the market yield on unsecured wholesale bank debt. These bank debt instruments, London branch deposits, are securities in the same sense that Treasuries are. And nobody questions that they are riskier than the U.S. Treasury bills. But as we learned, the LIBOR rate is not exactly the price at which these deposits are traded. For example if, for some foolish reason, roughly 10 of the 18 banks asked on a daily basis to provide LIBOR, undertook to bring three- and six-month LIBOR rates below the Treasury rates at those maturities, they could make that happen without a single transaction. We learned from the LIBOR scandal that 18 large banks have unfortunate employees that have been cursed with the task of providing an answer to the following imponderable question every day. ICE LIBOR Question: “At what rate could you borrow funds, were you to do so by asking for and then accepting interbank offers in a reasonable market size just prior to 11 am London time?” There is no compensation this side of $1 billion that would entice me to accept this job. The reason is simple. This person is very likely to be sued, perhaps criminally, and will have no credible economic explanation for the values provided. Consider the plight of this person if employed, for example, to produce Citibank’s (NYSE: C ) rate. Of the 18 banks polled each day, 17 know at what price Citibank could borrow under the (poorly specified) circumstances of the question. The only bank that does not is Citibank, which cannot lend to itself. Worse, none of the 18 banks know the minimum rate at which Citibank could borrow, which is the number requested. Yet this Citibank must make this guess every day. Given the disastrous events of recent years and the legal jeopardy described above, I am sure the LIBOR providers do their very best to guess this rate correctly these days. There is little likelihood that LIBOR is anything other than a very good guess at the 11:00 AM cost of bank money in London. The likelihood of LIBOR falling below the Treasury rate is nil. Why is the IRS rate different from LIBOR? Mostly because it is more obscure. Nobody is going to jail because the spread is out of line right now. But it is no less important to the dealer banks. Various authors search for an economic explanation for an IRS rate less than the Treasury rate. Resist this urge. There is no economic answer. The dominant economic explanation in the press doesn’t wash. This explanation posits that these unseemly low IRS rates are the result of the incredibly safe IRS clearing houses. The argument goes that the new OTC clearing facilities are less credit risky than the U.S. government. This dubious notion, it is suggested, is perhaps due to an implicit government guarantee, resulting from exchanges’ designation as “systemically important utilities.” Such explanations are based on a total misunderstanding of the credit risk associated with entering a swap and could not be more mistaken. IRS trades are credit risky. But the credit risk in question has no direct relationship to the IRS yield. The credit risk exists on both sides of the trade. Each party to the trade is at risk to the other. As a result, there is no reason for either side to pay for the credit risk it creates unless its credit risk is dramatically different from its counterparty. This is not the case for the dealer swap transactions upon which market pricing is based. The heart of the matter is that LIBOR swap rates are based on the dealers’ prices in trades with each other. For the specifics of how IRS prices are determined, l refer the reader to a rather terse explanation from LCH:Clearnet , the largest clearer of IRS globally. The root of the pricing problem is that IRS trades, like LIBOR, are not negotiable and thus inevitably guesses. LCH:Clearnet’s methodology does not specify the guesser. I have no reason to doubt that the effort to guess the market price of IRS is as sincere as that for LIBOR. I expect that the negative value of the Treasury/IRS spread caught the dealer’s attention and that the optics did not amuse them, another reason to believe the prices are close to the market’s transaction prices. Here is a short list of market issues that could be leading to the negative spread. (click to enlarge) Liquidity. As the Chart below indicates, the volume of cleared IRS has been falling steadily for the past two years. This suggests fewer dealer trades. JasonC also shows that U.S. dealer notional principal amounts (NPA) have been falling steadily over the same period, another indicator of falling liquidity in this market. The market may have become less efficient, and the dealers’ ability to change pricing as market conditions change may be reduced. Valuation Issues. An IRS (if you set the credit risk between parties aside) is a zero-sum game. Every dollar one trader earns as IRS rates change is lost by another. Since most IRS are trades between the 10 largest dealers, I cannot imagine that the trading community as a whole benefits directly from unchanging interest rates, whether up or down. The same may not be said of individual dealers of course, so the possibility that one or more specific banks is losing value as interest rates rise is real. But I don’t think one or a few banks losing money would slow the rise in IRS long-term rates. Changing rates do have a substantial and important indirect negative effect on all banks. There is a reporting issue associated with changing rates. Bank derivative risk reporting basically involves two measures of performance. Banks report their derivatives NPA and derivatives net asset value (cash value in the case of a hypothetical sale.) A run-up in interest rates has a substantial effect on every bank’s net asset value. It has no effect on the net asset value of the system as a whole, since every dollar earned in the zero-sum swap market is also lost elsewhere. But regulators base their estimates of the risk exposure of the banks’ swap books on this number. And both negative market values and positive market values rise as rates change. Even an increase in a bank’s swap book net asset value is a negative for bank regulators. This factor could create an incentive to moderate changes in swap rates, especially if there were a substantial probability that these increases would be reversed. The Whack-a-Mole Factor. Finally, I think it would not be surprising if individual banks are as reluctant in the IRS market as they are in the LIBOR market to release estimates of market yields higher or lower than the herd’s reported average. IRS estimated rates are no less subjective than LIBOR rates, since there are no secondary market prices. There has not been a scandal in IRS markets analogous to that in the LIBOR markets. In fact, this is one of the few OTC markets in which there has been no such scandal. But who wants to be first? All in all, I do not find this temporary divergence of IRS rates from their theoretical relationship to Treasury rates very alarming. None of my suggested reasons leads to any kind of financial disaster. But the absence of pricing efficiency in the IRS market is another of the gradually collecting indicators that this market is more expensive to operate and less efficient in performing its risk-transfer function than we should expect. And trading this spread based on bank credit risk estimates is dangerous right now. As presently constituted, the IRS market is hazardous to traders other than dealer banks and their customers. And that is its most important flaw.

Cancer Immunotherapy ETF Takes Curious Approach To Asset Allocation

Summary The Loncar Cancer Immunotherapy ETF was launched recently with the goal of targeting companies actively engaged in the treatment of cancer through immunotherapy. The fund’s investment in both healthcare mega-caps and biotech small-caps provide very different exposure to immunotherapy treatments. This fund looks more like a broader healthcare ETF than a pure play on cancer immunotherapy. The ETF world is becoming increasingly niche oriented lately and another niche ETF – the Loncar Cancer Immunotherapy ETF (NASDAQ: CNCR ) – recently joined the fray. Biotech has been a popular place to create a new product lately as ETFs targeting companies involved in genomics, drugs in late stage clinical trials and medical breakthroughs have all hit the market in the past 12 months. According to the fund’s fact sheet, the Cancer Immunotherapy ETF “is an equal-weighted index containing both large pharmaceutical and growth-oriented biotechnology companies that are leading in this approach.” It charges an expense ratio of 0.79% and equal weights the portfolio among 30 holdings. How it chooses those 30 holdings is what makes it curious. The fund commits around one third of its assets to some of the world’s biggest pharmaceutical companies that are developing immunotherapy treatment technologies. The remaining two thirds of assets are invested in biotechs that develop their own immunotherapy drugs and treatments. A look at the top holdings of the ETF shows a literal who’s who of the biggest healthcare companies in the world – Celgene (NASDAQ: CELG ), Pfizer (NYSE: PFE ), Amgen (NASDAQ: AMGN ) and Merck (NYSE: MRK ). As a result of the fund’s investment objective and stock selections, the ETF is one third invested in large- and mega-cap stocks and two thirds invested in small- and micro-cap stocks. The portfolio allocation and investing style suggests to me that this fund is more healthcare ETF and less cancer immunotherapy ETF. The mega-cap pharma companies in the portfolio may have cancer immunotherapy as part of their broad corporate strategy but by no means are these companies a pure play on this technology. Even the biotechs that are selected for inclusion in the portfolio have a somewhat low bar for what qualifies them for having exposure to cancer immunotherapy. As would be expected, these companies can have drugs in the pipeline whether they’re in later stage clinical trial or just starting out in the trial phase. But they also qualify if they have something as simple as a partnership with another company to work on developing immunotherapy treatment in the future. The fund’s portfolio makes it difficult to properly categorize this ETF. Its biotech allocation makes it a risky venture since many of these small companies may live or die on the success of a single drug. The significant exposure to the biggest pharmaceutical companies helps limit overall portfolio risk but provides little direct exposure to cancer immunotherapy since they have such broad, developed and diversified drug portfolios. Conclusion Investors looking for a pure play on cancer immunotherapy treatment technologies will likely be disappointed. The mega-cap presence in the portfolio provides a degree of safety for the fund but it also dilutes the exposure to immunotherapy. While many of the biotech holdings employ cancer treatment as a primary goal, there are a handful that have a more diversified drug pipeline further affecting the direct immunotherapy exposure. Individuals looking for more of a broad healthcare and biotech investment may find this choice in the ETF space intriguing but the level of direct exposure to cancer immunotherapy treatments makes this fund less than a pure play.

Glamour Stocks And Anchoring On The Changing P/E

Glamour stocks – Over the long-term, value investing as a style outperforms growth (if you’re looking for the evidence to support this statement, you can find it here , here and here ). We’ve known this to be the case for the past five decades. Why then does growth remain a popular strategy? This question formed the basis of a recent study conducted by Anderson, Keith P. and Zastawniak, Tomasz. The results of the study were published at the end of October in a paper entitled, Glamour, Value and Anchoring on the Changing P/E . Citation: Anderson, Keith P. and Zastawniak, Tomasz, Glamour, Value and Anchoring on the Changing P/E (October 23, 2015). Available at SSRN . Glamour, Value and Anchoring on the Changing P/E It has been known since 1960 that a portfolio of low P/E ‘value’ shares will produce better returns than a portfolio of high P/E ‘glamour/growth’ shares (Nicholson, S.F. 1960. Price-earnings ratios. Financial Analysts Journal, 16(4): 43-45.). Many studies have attempted to establish why this is the case but most of these studies have had one key flaw. Indeed, the studies in question have all revolved around the belief that value shares are riskier than glamour shares, which isn’t true. Shleifer and Vishny (Lakonishok, J., Shleifer, A. & Vishny, R. 1994. Contrarian investment, extrapolation, and risk. The Journal of Finance, 49(5): 1541-78.) concluded that value shares are not fundamentally riskier than glamour shares and they went on to give one possible behavioral explanation as to why investors may prefer glamour stocks: they want to appear more prudent. In other words, because glamour shares have been going up in the period before buying, their acquisition is easier to justify. Anderson, Keith P. and Zastawniak, Tomasz argue that a different behavioral explanation is behind the value/glamour split – a well-known feature of investors’ own bounded rationality: anchoring . “Investors may anchor on the P/E ratio currently attached to a stock when they invest in it. Having bought the stock, they expect the P/E to change slowly, if at all. As time goes on, the P/E decile changes, and different prospects for returns attach to each decile. If there is a differential drift in the P/E and hence returns between value and glamour stocks that is not expected by investors, this could account for why glamour investors end up disappointed.” – Glamour, Value and Anchoring on the Changing P/E . (click to enlarge) (click to enlarge) Glamour stocks vs. value Source: Brandes Institute titled, ” T he Role Of Expectations In Value And Glamour Stock Returns. ” Glamour stocks: Three questions With this hypothesis in place, Anderson, Keith P. and Zastawniak, Tomasz focused their research on answering three fundamental questions: Is there justification for the P/Es of value and glamour shares to change at different rates and the fact that value shares outperform glamour shares? What are the observed changes in P/Es and the returns that attach to them, and do investors’ decisions appear to be affected by anchoring ? Can glamour shares’ returns match or exceed those of value shares over any time period? With respect to question one, the study finds that by applying option pricing theory and Merton’s model to prices, and thus P/Es, of value and glamour shares can indeed be expected to move differently. The answer to question two is that glamour shares give three times the returns of value shares if they stay in the same decile, but they have a much greater tendency to move decile, which seems to be the reason behind value’s historical outperformance. Moreover, glamour investors appear to be underestimating the tendency of their shares to change P/E decile by at least 18%. This helps answer question three. Based on the study’s research, glamour investors will be subject to unimpressive returns whatever their time horizon. Glamour stocks: Key findings The major findings of Anderson, Keith P. and Zastawniak, Tomasz’s paper are rather interesting. The paper concludes that the main reason many investors continue to buy glamour shares is because they perceive the high P/E ratios of glamour stocks to be more permanent than they really are. A result of investors’ own behavioural bias of anchoring on the high initial values. However, glamour stocks whose P/E remained elevated throughout the study did outperform value stocks over the same period. Nevertheless, the tendency for the P/E of glamour stocks to change suddenly, and without notice, explains why glamour investors have, and will continue to see poorer returns than those following a value strategy. Disclosure: None